Sol-Gel Technologies (SLGL) Total Debt (2016 - 2025)

Sol-Gel Technologies (SLGL) posted quarterly Total Debt of $1.4 million for Q2 2025, down 97.93% quarter-over-quarter from $65.3 million in Q4 2017.

Sol-Gel Technologies (SLGL) Total Debt (2016 - 2025) Analysis & Trends

Sol-Gel Technologies (SLGL) has reported Total Debt for 3 consecutive years, with $1.4 million the latest figure, recorded in Q2 2025.

In Q2 2025, Total Debt changed N/A year-over-year to $1.4 million; the TTM figure through Jun 2025 stood at $1.4 million (changed N/A YoY), while the FY2017 annual figure was $65.3 million, up 74.99% from the prior year.
Total Debt eased to $1.4 million in Q2 2025 per SLGL's latest filing, from $65.3 million in the prior quarter.
Across five years, Total Debt topped out at $1.4 million in Q2 2025 and bottomed at $1.4 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Sol-Gel Technologies	240.26 Mn	230.12 Mn	-	-

Download Data